Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02211196 · ClinicalTrials.gov registry record · NA

Evidence-Based Tobacco Cessation Strategies in Patients With Cancer

A NA study of Malignant Neoplasm, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
NA
Development phase
377
Enrollment target
1
Study location

NCT02211196 is a NA study of Malignant Neoplasm that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 377 participants, below the 507-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02211196, a NA study of Malignant Neoplasm, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
NA
Development phase
377 participants
Enrollment target
1
Study location

Study Summary

This pilot clinical trial studies evidence-based tobacco cessation strategies in patients with cancer. Stop-smoking plans suggested by doctors may help patients with cancer quit smoking.

Conditions Studied

Interventions

  • OTHER questionnaire administration
  • OTHER survey administration
  • BEHAVIORAL smoking cessation intervention

Study Locations (1)

North Carolina

  • Comprehensive Cancer Center of Wake Forest University - Winston-Salem

Trial Details

FieldValue
Enrollment Target 377 participants
Start Date 2013-02
Est. Completion 2014-11
Phase NA

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT02211196

The ClinicalTrials.gov registry entry for NCT02211196 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 377 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 507-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (26% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which questionnaire administration is the first listed.

NCT02211196 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT02211196 about?

NCT02211196 is a clinical study titled "Evidence-Based Tobacco Cessation Strategies in Patients With Cancer". This pilot clinical trial studies evidence-based tobacco cessation strategies in patients with cancer. Stop-smoking plans suggested by doctors may help patients with cancer quit smoking.

What is the current status of trial NCT02211196?

This trial is currently completed. It is a NA study. The enrollment target is 377 participants. The study started on 2013-02. Estimated completion is 2014-11.

What conditions does trial NCT02211196 study?

This clinical trial studies the following conditions: Malignant Neoplasm.

What interventions are being tested in trial NCT02211196?

The interventions under investigation include: questionnaire administration (OTHER), survey administration (OTHER), smoking cessation intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT02211196?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02211196 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.